Valuation: Outlook Therapeutics, Inc.

Market Cap 18Cr 16Cr 15Cr 14Cr 26Cr 1.74TCr 26Cr 174.18Cr 68Cr 867.9Cr 69Cr 67Cr 2.91TCr P/E 2026 *
-2.06x
P/E 2027 * -5.05x
Enterprise Value 18Cr 16Cr 15Cr 14Cr 26Cr 1.74TCr 26Cr 174.18Cr 68Cr 867.9Cr 69Cr 67Cr 2.91TCr EV / Sales 2026 *
44.3x
EV / Sales 2027 * 3.15x
Free-Float
85.03%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Outlook Therapeutics, Inc.

1 day-6.10%
1 week-30.49%
1 month-38.58%
3 months+290.64%
6 months+122.11%
Current year-38.19%
1 week 0.82
Extreme 0.82
1.42
1 month 0.82
Extreme 0.82
1.87
Current year 0.16
Extreme 0.1611
1.88
1 year 0.16
Extreme 0.1611
3.39
3 years 0.16
Extreme 0.1611
34
5 years 0.16
Extreme 0.1611
65.4
10 years 0.16
Extreme 0.1611
878.4
Manager TitleAgeSince
Chief Executive Officer 54 01/07/2025
Chief Executive Officer 60 03/12/2024
Chief Tech/Sci/R&D Officer - 19/01/2023
Director TitleAgeSince
Director/Board Member 60 02/08/2018
Director/Board Member 65 11/12/2015
Chairman 41 31/01/2025
Date Insider Type Main position Quantity % Market Cap.
29/07/26 Buy

Chairman

95,398 0.0642%
21/07/26 Free

Chief Executive Officer

1,00,000 0.0673%
21/07/26 Free

Chief Financial Officer

2,10,078 0.1414%
Change 5-day change 1-year change 3-year change Capi.($)
-6.10%-30.49%-50.17%-97.18% 19Cr
-1.40%+2.59%-1.71%+11.28% 4.94TCr
-2.41%-0.90%+403.17%+614.40% 4.09TCr
-1.16%+12.96%+26.45%+5.03% 3.91TCr
-1.88%-3.03%+4.94%+47.52% 3.58TCr
-1.74%+5.12%+9.58%+46.02% 3.05TCr
-2.85%-3.92% - - 1.66TCr
-0.21%-4.04%+35.09%+127.95% 1.61TCr
-0.64%+2.65%+1.25%+8.92% 1.37TCr
-1.19%-1.32%-3.32%-34.94% 1.28TCr
Average -1.96%-1.47%+47.25%+81.00% 2.55TCr
Weighted average by Cap. -1.60%+3.15%+77.24%+128.65%

Financials

2026 *2027 *
Net sales 41.22L 35.83L 33.35L 30.62L 57.83L 39Cr 58.72L 3.93Cr 1.54Cr 20Cr 1.55Cr 1.51Cr 66Cr 5.8Cr 5.04Cr 4.69Cr 4.31Cr 8.14Cr 553.64Cr 8.26Cr 55Cr 22Cr 275.62Cr 22Cr 21Cr 924.21Cr
Net income -4.79Cr -4.17Cr -3.88Cr -3.56Cr -6.72Cr -457.46Cr -6.83Cr -46Cr -18Cr -227.74Cr -18Cr -18Cr -763.65Cr -3.23Cr -2.81Cr -2.62Cr -2.4Cr -4.54Cr -308.75Cr -4.61Cr -31Cr -12Cr -153.71Cr -12Cr -12Cr -515.41Cr
Net Debt - -
Logo Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. It is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.
Employees
17
Date Price Change Volume
31/26/31 $0.9766 -6.10% 80,74,274
30/26/30 $1.040 +4.00% 99,21,218
29/26/29 $1.000 +10.62% 2,85,46,582
28/26/28 $0.9040 -15.12% 3,48,71,066
27/26/27 $1.065 -24.20% 4,04,12,061
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.9766USD
Average target price
5.400USD
Spread / Average Target
+452.94%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OTLK Stock